Resumen de Fetal exposure to dasatinib in a pregnant woman with chronic myeloid leukemia
J. E. Megías, Eva Romá Sánchez, J. S. Rubio, Silvia Valero García, José Luis Poveda Andrés
Objective: To report a case of fetal exposure to dasatinib in chronic myeloid leukemia (CML). Case summary: A 34-year-old woman with CML who became pregnant while being treated with dasatinib during 20 months. Parents decided to continue with the pregnancy, despite the possible risks of 5-6 weeks fetal exposition to dasatinib. Treatment was switched to interferon after pregnancy was detected. Disease control was achieved throughout pregnancy without causing relapse and the patient gave birth to a healthy child. Discussion: Use of dasatinib is not recommended during pregnancy, although the actual risk of its use in humans is unknown and published literature on the topic is limited. The available cases reports seem to suggest that dasatinib probably increase fetal mortality (two spontaneous abortions) and congenital malformations (only one case). But, on the other hand, in five cases children were born without congenital malformations. Conclusion: The development of reports with evidence on potentially teratogenic drug exposure during pregnancy is essential for patient and clinician decision-making, specially when clinical experience is limited
